CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Licensee patent challenges represent a critical intersection between contractual agreements and patent law. This concept, ...

AstraZeneca and its wholly owned subsidiary MedImmune will leverage the Hybrozyme platform technology. ALT-B4 therapy ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

The Parainfluenza Virus Infection market is expected to surge due to the disease's increasing prevalence and awareness during ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy drug, according to a study in Cancer Cell. In addition, an analysis of the ...

S. Koreas biotech sector kicks off 2025 with multi-billion-dollar deals K-Bio firms secure nearly $2.3 billion in licensing ...

The biotechnology corporation Alteogen announced on the 17th that it signed a technology export contract with the global pharmaceutical company Astrazeneca's biopharmaceutical subsidiary MedImmune to ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...